<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04015258</url>
  </required_header>
  <id_info>
    <org_study_id>Research Ethics 10113</org_study_id>
    <nct_id>NCT04015258</nct_id>
  </id_info>
  <brief_title>Blueberry Study Aimed at Improving Cognition and Peripheral Blood Flow</brief_title>
  <official_title>Metabolic Mechanisms Underlying the Responsiveness to Blueberry Interventions Aimed at Improving Cognition and Peripheral Blood Flow</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northumbria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northumbria University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Blueberries are rich in the content of a variety of biologically active chemicals that
      contribute to their health properties. The consumption of blueberries has beneficial effects
      on vascular function and brain health and function. Blueberries are present in human diet in
      a number of forms, but the investigator do not know which form is best for health and why
      people respond differently to eating blueberries.

      The aim of the present study is to assess the effects of 1 week's supplementation of whole
      blueberries or freeze-dried blueberry powder or encapsulated blueberry components on vascular
      function and brain health and function. Investigators will then categorise participants as
      those who have large effects of the intervention (responders) and those that don't show much
      effect at all (non-responders). Then the investigators will look into the role that genes
      play in this response and determine if metabolism is similar in these groups of participants.
      Any changes in participants' brain health and vascular function will be linked to these
      metabolic and genomic pathways, and this will help the investigators to further understand
      how blueberry consumption can benefit human health.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: The present study will supply either 160 g of fresh whole blueberry (4 handful
      portion) or 20 g of freeze-dried blueberry powder (measured with tablespoon provided;
      equivalent to 160 g of whole fresh blueberry), or placebo capsule with only microcrystalline
      cellulose (approx. 10 g, they will be blinded that this is encapsulated blueberry extract
      components) to 80 subjects on separate occasions with age range of 18-60 years old for 1 week
      with 1 week of washout period. Fresh blueberries will be purchased from local supermarkets;
      freeze-dried blueberry powder will be purchased from Lio-Licious freeze-dried fruits range;
      the microcrystalline cellulose will be purchased from Blackburn Distributions. There is no
      outside interest that could constitute commercial conflict of interest.

      Methodology and sampling strategy: a randomised crossover design will be implemented. The
      study is a quantitative experiment and participants will be recruited through opportunity
      sampling.

      Data collection: On each visit, cognition data will be obtained from computerised testing
      system COMPASS. Blood pressure will be obtained using fully automatic oscillometric device.
      On visits 2-7, PWV value is obtained by SphygmoCor; untargeted metabolomics and genomic data
      will be obtained from blood and urine sample collection.

      For data analysis: The identification of responders to the treatments will be done by the
      calculation of response level first: response level = (change from baseline score/baseline
      score) x 100%. The calculated percentage will be used to characterise subjects from lowest
      response to highest response level. The association among -omics biomarkers and cognitive
      tests/endothelial parameters, lipid status under each treatment will be analysed using linear
      regression models after adjusting for confounding factors like age. Pathway analysis will be
      used to identify metabolic pathways that characterise responders and non-responders. Pathways
      will be identified using discriminatory metabolites from metabolomics and SNP analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Actual">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of participant recalling word list Immediately</measure>
    <time_frame>1 minute</time_frame>
    <description>will be assessed via COMPASS (Computerised Mental Performance Assessment System) tasks by participants recalling word list immediately after displays; the result will be presented as accuracy (%) and as an assessment of short-term memory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correct responses of participants counting down from certain number by subtracting 3</measure>
    <time_frame>5 minutes</time_frame>
    <description>will be assessed via COMPASS tasks by participants counting down from certain number by threes. The result will be presented as correct responses and as an assessment of executive function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correct responses of participants counting down from certain number by subtracting 7</measure>
    <time_frame>5 minutes</time_frame>
    <description>will be assessed via COMPASS tasks by participants counting down from certain number by sevens, the result will be presented as correct responses and as an assessment of executive function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reaction time of participants' vigilance during rapid visual tracking and accurate selection of target digit stimuli</measure>
    <time_frame>5 minutes</time_frame>
    <description>will be assessed via COMPASS tasks by measuring participants' vigilance during rapid visual tracking and accurate selection of target stimuli, presented by reaction time in millisecond (ms), as an assessment of attention and psychomotor speed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accuracy of participant recalling word list 30 minutes after displays</measure>
    <time_frame>5 minutes</time_frame>
    <description>will be assessed via COMPASS tasks by participants recalling word list after 30 minutes, the result will be presented as accuracy (%) and as an assessment of memory</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brachial-radial distance</measure>
    <time_frame>1 minute</time_frame>
    <description>brachial-radial distance in meters (m), will be measured by tape</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse wave time</measure>
    <time_frame>10 minutes</time_frame>
    <description>time of the pulse wave moves down from brachial to radial artery in seconds (s), will be measured by Sphygmocor (ScanMed medical)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse wave velocity (PWV)</measure>
    <time_frame>10 minutes</time_frame>
    <description>will be measured by Sphygmocor (ScanMed medical), by outcome 7 pulse wave time (s) dividing outcome 6 brachial-radial distance (m), PWV will be presented in the units of m/s, as an assessment of endothelial function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>10 minutes</time_frame>
    <description>will be assessed by BP monitor and reported in the units of mm Hg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inter-cellular Adhesion Molecules (ICAMs) and Vascular Cell Adhesion Molecules (VCAMs)</measure>
    <time_frame>1 day</time_frame>
    <description>Endothelial dysfunction's biomarkers (ICAMs and VCAMs) assessed by ELISA Kits and reported in the units of U/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive Protein (CRP)</measure>
    <time_frame>1 day</time_frame>
    <description>Endothelial dysfunction's biomarkers (CRP) assessed by ELISA Kits in the units of mg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Lipid Status</measure>
    <time_frame>1 day</time_frame>
    <description>Total and High-density lipoprotein (HDL-), Low-density lipoprotein (LDL-) cholesterol and triglycerides assessed by outsourcing to the local hospital, the results will be reported in the units of mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Untargeted Plasma and Urine Metabolites</measure>
    <time_frame>1 day</time_frame>
    <description>liquid-chromatography mass spectrometry-based techniques (LCMS) will be applied to identify untargeted metabolites in the plasma and urine samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Nucleotide Polymorphisms (SNPs)</measure>
    <time_frame>7 days</time_frame>
    <description>SNP arrays will be applied for genotyping participants' DNA collected from the buffy coat of the blood sample, following the removal of plasma</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Vascular Stiffness</condition>
  <condition>Cognitive Change</condition>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Blueberries</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fresh blueberries purchased from local supermarket will be distributed to each participant for 1 week's consumption, 160 grams per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blueberry powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Freeze-dried blueberry powder will be distributed to each participant for 1 week's consumption, 20 grams per day, equivalent to 160 grams of fresh blueberries</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blueberry components capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Encapsulated microcrystalline cellulose powder will be blinded as blueberry components capsules to be distributed to each participant for 1 week's consumption</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Blueberries</intervention_name>
    <description>fresh spanish blueberries</description>
    <arm_group_label>Blueberries</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Blueberry powder</intervention_name>
    <description>freeze-dried blueberry powder</description>
    <arm_group_label>Blueberry powder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Blueberry components capsules</intervention_name>
    <description>encapsulated blueberry components (microcrystalline cellulose powder in actual)</description>
    <arm_group_label>Blueberry components capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Interested in taking part in the study

          -  Healthy

          -  Aged 18-60 years (inclusive)

        Exclusion Criteria:

          -  Smoking

          -  Aged under 18 or over 60

          -  Blood Pressure â‰¥ 145/100 mmHg and are taking medication

          -  Have vascular disease, or other cardiac abnormalities

          -  Have previously suffered any head injuries, history of seizures or other neurological
             disorders

          -  Have any metabolic disorders, malabsorption syndromes or gastrointestinal
             complications

          -  Current use of above disease relevant prescription medications (excluding
             contraception)

          -  Irregular bowel function (less than 1 bowel movement per day)

          -  Regularly consume blueberries/blueberry-contained products more than twice per week

          -  Have regularly used nutritional supplements or medications within the previous 3
             months (defined as more than 3 consecutive days or 4 days in total)

          -  Learning difficulties and dyslexia

          -  Visual impairment that cannot be corrected with glasses or contact lenses including
             colour blindness

          -  Currently suffer from migraines (&gt; 1 per month)

          -  Body mass index (BMI) under 18.5 or over 30

          -  Pregnancy, seeking to become pregnant, or current lactation

          -  Inability to complete all of the study assessments

          -  Current participation in other clinical or nutrition intervention studies

          -  Not proficient in English equivalent to IELTS band 6 or above

          -  Have any known active infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yueyue Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Miss</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northumbria University</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <state>Tyne And Wear</state>
        <zip>NE1 8ST</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 4, 2019</study_first_submitted>
  <study_first_submitted_qc>July 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2019</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>blueberry</keyword>
  <keyword>intervention</keyword>
  <keyword>endothelial function</keyword>
  <keyword>cognition</keyword>
  <keyword>metabolomics</keyword>
  <keyword>genomics</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

